Clinical trial
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
NCT00098514 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00098514 |
|---|---|
| Title | Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors |
| Official title | A Phase I Study Of PT523 In Patients With Solid Tumors |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | talotrexin ammonium |
| Enrollment | 53 |
| Start date | Dec 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | May 1, 2011 |
| First posted | Dec 8, 2004 |
| Last update posted | Dec 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: